The role of cetuximab in the therapy of previously treated advanced colorectal cancer (vol 32, pg S55, 2005)

被引：0
|
作者：
Chong, Geoff
Cunningham, David
机构：
来源：
SEMINARS IN ONCOLOGY | 2006年 / 33卷 / 04期
关键词：
D O I：
10.1053/j.seminoncol.2006.06.012
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：521 / 521
页数：1
相关论文
共 50 条
  • [1] The role of cetuximab in the therapy of previously treated advanced colorectal cancer
    Chong, G
    Cunningham, D
    [J]. SEMINARS IN ONCOLOGY, 2005, 32 (06) : S55 - S58
  • [2] The epidermal growth factor receptor as a target for colorectal cancer therapy (vol 32, pg 52, 2005)
    Lockhart, AC
    [J]. SEMINARS IN ONCOLOGY, 2005, 32 (04) : 432 - 432
  • [3] Impact of UK colorectal cancer screening pilot on primary care (vol 55, pg 20, 2005)
    Jepson, R
    Weller, D
    Alexander, F
    Walker, J
    [J]. BRITISH JOURNAL OF GENERAL PRACTICE, 2005, 55 (512): : 234 - 234
  • [4] Definition of oxaliplatin sensitivity in patients with advanced colorectal cancer previously treated with oxaliplatin-based therapy
    de Gramont Lesparre, A. H.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A. K.
    Afchain, P.
    Louvet, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [5] Genetic Susceptibility to Prostate, Breast and Colorectal Cancer among Nordic Twins (vol 61, pg 55, 2005)
    Baker, Stuart G.
    Lichtenstein, Paul
    Kaprio, Jaakko
    Holm, Niels
    [J]. BIOMETRICS, 2012, 68 (03) : 993 - 993
  • [6] DEFINITION OF OXALIPLATIN SENSITIVITY IN PATIENTS WITH ADVANCED COLORECTAL CANCER PREVIOUSLY TREATED WITH OXALIPLATIN-BASED THERAPY
    de Gramont, A.
    Chibaudel, B.
    Bourges, O.
    Perez-Staub, N.
    Tournigand, C.
    Maindrault-Goebel, F.
    Andre, T.
    Larsen, A.
    Afchain, P.
    Louvet, C.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 13 - 13
  • [7] Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
    Meyerhardt, Jeffrey A.
    Ancukiewicz, Marek
    Abrams, Thomas A.
    Schrag, Deborah
    Enzinger, Peter C.
    Chan, Jennifer A.
    Kulke, Matthew H.
    Wolpin, Brian M.
    Goldstein, Michael
    Blaszkowsky, Lawrence
    Zhu, Andrew X.
    Elliott, Meaghan
    Regan, Eileen
    Jain, Rakesh K.
    Duda, Dan G.
    [J]. PLOS ONE, 2012, 7 (06):
  • [8] Panitumumab monotherapy compared with cetuximab and irinotecan combination therapy in patients with previously treated KRAS wild-type metastatic colorectal cancer
    Kennecke, H.
    Chen, L.
    Blanke, C. D.
    Cheung, W. Y.
    Schaff, K.
    Speers, C.
    [J]. CURRENT ONCOLOGY, 2013, 20 (06) : 326 - 332
  • [9] The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer
    Watkins, David
    Cunningham, David
    [J]. CLINICAL COLORECTAL CANCER, 2007, 6 : S47 - S52
  • [10] Human gene therapy and imaging in neurological diseases (vol 32, pg S358, 2005)
    Jacobs, AH
    Winkler, A
    Castro, MG
    Lowenstein, P
    [J]. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (03) : 390 - 390
12345